In this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I clinical trials nurse practitioner, engage in a multidisciplinary discussion of the latest management strategies for EGFR-mutated non-small-cell lung cancer, including the evolving treatment landscape for disease resistant to standard-of-care EGFR TKI inhibitors.
In this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I clinical trials nurse practitioner, engage in a multidisciplinary discussion of the latest management strategies for EGFR-mutated NSCLC. Topics include:
Presenters:
Conor Ernst Steuer, MD
Assistant Professor
Department of Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia
Frank Schneider, MD
Associate Professor of Pathology
Department of Pathology and Laboratory Medicine
Director, Cancer Tissue and Pathology Shared Resource
Winship Cancer Institute
Emory University
Atlanta, Georgia
Elise Hitron, MSN, FNP-C
Adjunct Instructor
School of Nursing
Phase I Clinical Trials Nurse Practitioner
Winship Cancer Institute
Emory University
Atlanta, Georgia
Supported by an educational grant from Daiichi Sankyo, Inc.
Link to full program, including a series of short interactive virtual presentations with downloadable slidesets on EGFR-mutated advanced NSCLC, including the evolving role of HER3 in the setting of EGFR TKI resistance:
https://bit.ly/3G32Jkm